In the past decade, cerebrospinal fluid (CSF) orexin-A levels have been thus measured in patients with mild cognitive impairment (MCI) and dementia, particularly those with Alzheimer’s disease (AD) and frontotemporal dementia (FTD) [9–18]. Here, HCRT is linked to frontotemporal dementia.